Zika virus vaccine - Themis Bioscience

Drug Profile

Zika virus vaccine - Themis Bioscience

Alternative Names: MV-ZIKA; MV-Zika vaccine

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Themis Bioscience
  • Class Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 16 Dec 2016 Themis Bioscience plans a phase I trial for Zika virus infections in Austria (NCT02996890)
  • 13 Dec 2016 Preclinical trials in Zika virus infection in Austria (Parenteral) before December 2016 (NCT02996890)
  • 12 Jul 2016 Themis Bioscience enters into an extended licensing agreement with Institut Pastuer for virus vaccine vector technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top